Literature DB >> 22498581

Thyroid fine needle aspirate: a post-Bethesda update.

Shikha Bose1, Ann E Walts.   

Abstract

The Bethesda system for reporting thyroid cytopathology formulated in 2007 has standardized reporting of thyroid cytology specimens and streamlined management algorithms. Although 3 of the categories (benign, malignant, and nondiagnostic) are standardized and improved, the remaining 3 (follicular lesion of undetermined significance, follicular neoplasm, and suspicious for malignancy) remain fraught with interobserver variability and uncertainty regarding management algorithms. Recent and ongoing morphologic and molecular studies that aim to resolve these issues are summarized.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498581     DOI: 10.1097/PAP.0b013e3182534610

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  4 in total

1.  The 5-tiered categorization system for reporting cytology is sufficient for management of patients with thyroid nodules compared to the 6-tiered Bethesda system.

Authors:  Jieun Koh; Hee Jung Moon; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

2.  Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.

Authors:  Rengyun Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2014-08-13       Impact factor: 5.678

Review 3.  Evaluation of thyroid nodules by shear wave elastography: a review of current knowledge.

Authors:  K Z Swan; V E Nielsen; S J Bonnema
Journal:  J Endocrinol Invest       Date:  2021-04-16       Impact factor: 4.256

4.  The Bethesda system for reporting thyroid cytopathology in Colombia: Correlation with histopathological diagnoses in oncology and non-oncology institutions.

Authors:  Mario Alexander Melo-Uribe; Álvaro Sanabria; Alfredo Romero-Rojas; Gabriel Pérez; Elga Johanna Vargas; María Claudia Abaúnza; Víctor Gutiérrez
Journal:  J Cytol       Date:  2015 Jan-Mar       Impact factor: 1.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.